scientific reports



Published online: 11 July 2022

OPEN Author Correction: Foot-ankle therapeutic exercise program can improve gait speed in people with diabetic neuropathy: a randomized controlled trial

Renan L. Monteiro, Jane S. S. P. Ferreira, Érica Q. Silva, Ronaldo H. Cruvinel-Júnior, Jady L. Veríssimo, Sicco A. Bus & Isabel C. N. Sacco

Correction to: Scientific Reports https://doi.org/10.1038/s41598-022-11745-0, published online 09 May 2022

The original version of this Article contained errors in Table 2. In the columns 'Intervention Group' and 'Control Group', the mean and standard deviation values were reported, instead of the estimated mean and standard error values. The original Table 2 and accompanying legend appear below. As a result, in the Supplementary Tables file, Table 1 contained the same errors.

The original Supplementary Tables file is provided below.

The original Article and accompanying Supplementary Information file have been corrected.

	Intervention Group Means ± SD	Control Group Means ± SD	p-value	95% CI for Estimated Mean Difference	Effect size
Daily physical activity	(stens)				(95% CI) -2 -1.5 -1 -0.5 0 0.5 1 1.5
12 weeks	8.367 ± 4.418	7.385 ± 3.137	0.294	1.371 [-1.204, 3.946]	1.5 1 0.5 0 0.5 1 1.5
24 weeks	7.446 ± 3.525	7.072 ± 3.898	0.222	1.677 [-1.029, 4.383]	•
1 year	8.458 ± 4.206	7.093 ± 2.532	0.109	3.402 [-0.777, 7.580]	•
Fast gait speed (m/s)					
6 weeks	1.56 ± 0.27	1.44 ± 0.32	0.073	0.15 [-0.01, 0.31]	
12 weeks	1.65 ± 0.36	1.47 ± 0.37	0.020*	0.19 [0.31, 0.36]	•
24 weeks	1.59 ± 0.26	1.53 ± 0.44	0.873	0.02 [-0.16, 0.19]	•
1 year	1.43 ± 0.19	1.45 ± 0.31	0.027*	0.31 [0.35, 0.57]	
Self selected gait spec	ed (m/s)				
6 weeks	1.04 ± 0.24	1.04 ± 0.18	0.797	-0.01 [-0.13, 0.10]	
12 weeks	1.07 ± 0.15	0.98 ± 0.21	0.383	0.06 [-0.06, 0.17]	• • •
24 weeks	1.04 ± 0.14	1.04 ± 0.26	0.599	-0.04 [-0.18, 0.10]	
1 year	0.99 ± 0.12	1.05 ± 0.13	0.464	-0.09 [-0.33, 0.15]	
MNSI (score)					
6 weeks	6.5 ± 2.2	6.1 ± 2.4	0.711	0.3 [-1.0, 1.4]	
12 weeks	5.9 ± 1.9	5.7 ± 2.2	0.945	-0.1 [-1.2, 1.2]	
FHSQ - foot pain (scor		3.7 _ 2.2	0.5 .5	0.1 [1.2, 1.2]	
6 weeks	62.5 ± 24.7	59.1 ± 26.0	0.470	5.2 [-9.0, 19.5]	
12 weeks	69.2 ± 20.8	62.2 ± 25.4	0.470	11.2 [-3.4, 25.7]	
FHSQ - foot function (02.2 ± 23.4	0.132	11.2 [-3.4, 23.7]	
		69.0 ± 25.4	0.261	6 2 [7 2 10 0]	
6 weeks	75.6 ± 23.6	68.0 ± 25.4	0.361	6.2 [-7.2, 19.8]	
12 weeks	80.9 ± 21.9	75.3 ± 23.9	0.196	9.2 [-4.7, 23.1]	
FHSQ – shoes (score)	20.0 . 20.0	40.0 + 00.0	0.045	10.0 [00.4 7.5]	
6 weeks	39.8 ± 30.8	48.0 ± 32.2	0.245	-10.9 [-29.4, 7.5]	
12 weeks	46.5 ± 35.4	42.2 ± 31.5	0.807	2.3 [-16.7, 21.5]	
FHSQ - Foot Health (s					
6 weeks	36.2 ± 22.5	42.6 ± 29.0	0.723	2.5 [-11.4, 16.4]	•
12 weeks	41.3 ± 19.3	44.4 ± 30.6	0.787	1.9 [-12.2, 16.1]	•
Ankle plantaflexion R					
6 weeks	32.4 ± 6.5	32.1 ± 6.8	0.933	-0.1 [-3.9, 3.6]	•
12 weeks	33.6 ± 6.8	30.3 ± 5.8	0.337	2.0 [-2.0, 5.8]	•
Ankle dorsiflexion RO	• • • • • • • • • • • • • • • • • • • •				
6 weeks	19.4 ± 4.9	17.5 ± 5.6	0.414	1.3 [-1.8, 4.3]	•
12 weeks	20.0 ± 5.4	17.8 ± 4.8	0.349	1.5 [-1.7, 4.8]	· · · · · ·
Tactile					
6 weeks	2.1 ± 2.5	1.9 ± 2.9	0.514	-0.4 [-1.6, 0.8]	•
12 weeks	2.7 ± 2.5	2.0 ± 2.7	0.884	-0.1 [-1.3, 1.1]	
Tactile - threshold - L					
6 weeks	3.7 ± 1.6	3.7 ± 1.6	0.781	0.1 [-0.7, 0.9]	• • • • • • • • • • • • • • • • • • • •
12 weeks	3.7 ± 1.7	3.8 ± 1.8	0.960	0.0 [-0.8, 0.8]	
Vibration – L					
6 weeks	1.3 ± 0.7	1.3 ± 0.7	0.865	0.0 [-0.4, 0.4]	· · · · ·
12 weeks	1.5 ± 0.8	1.5 ± 0.8	0.030*	-0.1 [-0.9,05]	· · · · · ·
Quality of life (score)					
6 weeks	0.68 ± 0.14	0.63 ± 0.13	0.393	0.04 [-0.05, 0.13]	••••
12 weeks	0.70 ± 0.18	0.69 ± 0.17	0.312	0.05 [-0.04, 0.15]	· · · · · · · · · · · · · · · · · · ·
Hallux strength (%BW			-	,	
6 weeks	12.6 ± 6.1	12.3 ± 4.9	0.971	-0.1 [-2.9, 2.8]	· · · · ·
12 weeks	12.7 ± 5.9	11.5 ± 3.8	0.301	1.6 [-1.3, 4.4]	· · · · · ·
Toes strength (%BW)	12.7 2 3.3	11.5 ± 5.0	0.501	1.0 [1.0, 7.7]	
6 weeks	9.7 ± 5.0	8.8 ± 5.2	0.985	0.0 [-2.3, 2.4]	• • •
					· · · · · ·
12 weeks	10.1 ± 5.8	8.3 ± 4.7	0.349	1.0 [-1.2, 3.6]	

 Table 2. Secondary and primary outcomes from intervention group and control groups.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-16172-9.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022